Humana (HUM) Star Ratings Rebound Signals Stronger Path Ahead
Key Takeaways
- Humana reported that 95% of its Medicare Advantage members are now enrolled in plans rated at least four stars for 2027, a sharp rebound from roughly 20%–25% in recent years.
- The improved ratings restore Humana's eligibility for government quality bonus payments, a central pillar of the company's multi-year margin recovery plan.
- Shares surged to a 52-week high on the news, building on analyst upgrades and price-target increases from firms including Oppenheimer and Cantor Fitzgerald.
- Management reaffirmed its full-year 2026 adjusted earnings guidance of at least $9.00 per share.
- The company expects a portion of the 2028 benefit to fund one-time investments and returns to shareholders.
Market Reaction to the Latest Ratings
Humana shares moved sharply higher in the latest session following the Centers for Medicare and Medicaid Services release of final 2027 Medicare Advantage Star Ratings. The stock posted a double-digit intraday gain, reaching a fresh 52-week high and reflecting improved investor sentiment around the insurer’s quality turnaround. The gains stood out against several peers that saw declines in their own ratings outcomes.
This shift highlights how star ratings directly influence bonus revenue and market positioning in the managed-care space. For Humana, the results represent a clear step forward from the setback two years ago, when the share of members in four-star-or-better plans dropped from more than 90% to about 25%. Investors appear to be factoring in a more sustainable earnings recovery.
Humana’s Core Business and Market Role
Humana Inc. ranks among the largest U.S. health insurers, with Medicare Advantage serving as its primary focus. The company provides Medicare Advantage plans, Medicare Supplement products, and standalone prescription drug plans to individuals and employer groups. It also covers Medicaid beneficiaries and military families via the TRICARE program and runs a pharmacy benefit management operation.
Through its CenterWell segment, Humana delivers direct care services such as primary care, home health, and hospice, allowing it to capture value across the care continuum. Membership is concentrated in states including Florida, Texas, and Ohio. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The company’s heavy exposure to government programs means regulatory shifts, reimbursement rates, and star-ratings results carry particular weight for revenue and margins.
Factors Behind the Recent Strength
The main catalyst came with the October 2026 publication of final 2027 Medicare Advantage Star Ratings by CMS. Humana stated that 95% of its members are now in plans rated four stars or higher, up from roughly 20% for 2026, with 42% in plans rated 4.5 stars or higher. These figures surpassed the company’s top-quartile target and exceeded analyst forecasts. Oppenheimer estimated the difference could generate roughly $3.6 billion in revenue, which would support earnings if not fully passed through in bids.
The ratings improvement restores eligibility for quality bonus payments across a substantial portion of membership. Higher-rated plans also tend to draw and retain more members, aiding revenue growth and the company’s goal of unlocking earnings potential by 2028. Analyst commentary has been positive. Oppenheimer lifted its price target to $475 from $405 while keeping an Outperform rating, describing Humana as the “biggest winner” from the new ratings. Cantor Fitzgerald upgraded the stock to Overweight from Neutral with a $460 target, pointing to expected star-score gains. Management reaffirmed its 2026 adjusted earnings guidance of at least $9.00 per share, in line with the July 2026 update.
Key Items to Monitor Going Forward
Several elements will influence Humana’s path. Investors will track how effectively the star-ratings gains translate into lasting earnings growth and how much of the 2028 benefit is retained versus reinvested. Management plans to share more on the size and intended use of the one-time 2028 benefit once it has clearer visibility into competitive dynamics and the rate environment.
Humana has set a virtual investor update for December 10, 2026, to provide an update relative to the framework from its 2025 Investor Day. Broader Medicare Advantage challenges, such as medical cost trends, utilization, reimbursement decisions, and competition from peers including UnitedHealth, CVS Health, Elevance Health, and Centene, remain relevant. Quarterly results and any revisions to 2026 or 2028 guidance will also draw attention as the company finalizes results for the period ended September 30, 2026.
Using Data-Driven Tools in Analysis
In my own research, I often review Tickeron’s Trending AI Robots to gauge how automated strategies are positioned around names like this. The page features a selection of top-performing bots across different strategies, holding periods, and performance metrics, offering a practical way to see how algorithmic approaches interpret shifting conditions. It serves as a helpful complement when evaluating opportunities alongside traditional fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HUM saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for HUM moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 44 of the 65 cases the stock moved lower. This puts the odds of a downward move at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
HUM broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on HUM as a result. In 51 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for HUM just turned positive on October 05, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.
HUM moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HUM crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 223 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 178 of 239 cases where HUM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.435) is normal, around the industry mean (3.247). P/E Ratio (36.827) is within average values for comparable stocks, (139.958). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.009) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company offers health insurance coverage and related services
Industry ManagedHealthCare
Advertisement